Daiichi initiates arbitration proceedings against Singhs of Ranbaxy but is it more symbolic?
This article was originally published in Scrip
Executive Summary
Following through on its May 22 statement, Daiichi Sankyo is said to have moved towards initiating arbitration proceedings in Singapore against the former shareholders of Ranbaxy Laboratories, the Singh brothers, over alleged misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against Ranbaxy at the time of the 2008 takeover by the Japanese company.
You may also be interested in...
Golden Week For Daiichi: Damages Due From Ranbaxy Brothers
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore against the Singh brothers of Ranbaxy have gone the Japanese firm's way.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet